BioTime CEO Dr. Michael West to Present at 11th Annual Commercial Translation of Regenerative Medicine Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 25, 2013--
BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and
markets products in the field of regenerative medicine, today announced
that Chief Executive Officer Michael D. West, PhD will present at the 11th
Annual Commercial Translation of Regenerative Medicine conference in
London on Monday, November 25, 2013.
Dr. West’s presentation titled “Strategies for the Manufacture of Highly
Purified and Identified Products from Pluripotent Stem Cells" is
scheduled for 2:30 p.m. London Time. Topics discussed will include:
• The generation of clonal human embryonic progenitor (hEP) cell lines
• Fate space screening to discover novel differentiation pathways
• Examples of novel hEP lines with potential clinical utility
In particular, Dr. West will discuss the use of BioTime’s PureStem™
technology to manufacture young cells from specific locations in the
body. He will show data on diverse types of fat cells produced by
BioTime scientists from human embryonic stem cells. One example will be
data on the production of cells with molecular markers consistent with a
rare and important cell type called “brown fat” cells. Brown fat cells
are of great interest to medical researchers since in animal models of
obesity and Type II diabetes, these cells show evidence of reducing body
fat and increasing the body’s sensitivity to insulin. Dr. West will show
that certain PureStem™ cell lines can be induced to express two
important genes, one called “betatrophin” shown to induce the production
of new insulin-producing cells, and “adiponectin” a gene believed to be
important in protecting the body from deleterious effects of obesity.
The presentation will be made available on BioTime's website at www.biotimeinc.com.
About BioTime, Inc.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime’s focus is on pluripotent stem cell technology based on
human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”)
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of proprietary
PureStem™ progenitors, HyStem® hydrogels, culture
media, and differentiation kits. BioTime is developing Renevia™ (a
HyStem® product) as a biocompatible, implantable
hyaluronan and collagen-based matrix for cell delivery in human clinical
applications. In addition, BioTime has developed Hextend®,
a blood plasma volume expander for use in surgery, emergency trauma
treatment and other applications. Hextend® is
manufactured and distributed in the U.S. by Hospira, Inc. and in South
Korea by CJ CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell products for research and
therapeutic use through its subsidiaries:
Asterias Biotherapeutics, Inc. is a new subsidiary which has acquired
the stem cell assets of Geron Corporation, including patents and other
intellectual property, biological materials, reagents and equipment
for the development of new therapeutic products for regenerative
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
Cell Cure Neurosciences Ltd. (“Cell Cure Neurosciences”) is an
Israel-based biotechnology company focused on developing stem
cell-based therapies for retinal and neurological disorders, including
the development of retinal pigment epithelial cells for the treatment
of macular degeneration, and treatments for multiple sclerosis.
LifeMap Sciences, Inc. (“LifeMap Sciences”) markets, sells and
distributes GeneCards®, the leading human
gene database, as part of an integrated database suite that also
includes the LifeMap Discovery™ database of embryonic
development, stem cell research and regenerative medicine, and
MalaCards, the human disease database.
ES Cell International Pte Ltd., a Singapore private limited company,
developed hES cell lines and may market those cell lines and other
BioTime research products in over-seas markets as part of BioTime’s
ESI BIO Division.
OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of cardiovascular and related ischemic disorders, as well as products
for research using cell reprogramming technology.
Additional information about BioTime can be found on the web at www.biotimeinc.com.
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com
Source: BioTime, Inc.
Lesley Stolz, 510-521-3390 ext. 367
Vice President Corporate Development
Segall, 510-521-3390 ext. 301